



UNITED STATES PATENT AND TRADEMARK OFFICE

AT
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/362,598	07/28/1999	JOEL V. WEINSTOCK	3948/79934	7062

29933 7590 06/10/2004

PALMER & DODGE, LLP
KATHLEEN M. WILLIAMS
111 HUNTINGTON AVENUE
BOSTON, MA 02199

EXAMINER

ZEMAN, ROBERT A

ART UNIT	PAPER NUMBER
	1645

DATE MAILED: 06/10/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/362,598	WEINSTOCK ET AL.	
	Examiner	Art Unit	
	Robert A. Zeman	1645	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 03 November 2003.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 24,26 and 28-32 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 24,26 and 28-32 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 11-3-2004.
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: _____.

DETAILED ACTION

The amendment and response filed on 11-3-2003 are acknowledged. Claim 32 has been amended. Claims 24, 26, and 28-32 are pending and currently under examination.

Information Disclosure Statement

The amendment filed on 11-3-2003 (originally filed on 3-24-2003) is acknowledged. An initialed copy is attached hereto.

Claim Rejections Withdrawn

The rejection of claim 32 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention is withdrawn in light of the amendment thereto.

Claim Rejections Maintained and New Grounds of Rejection

35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The rejection of claims 24, 26 and 28-32 under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an *in vitro* method of determining the immune response ^{to} the co-infection of mice with *M. avium* and *S. mansoni* (either with or without TNBS

treatment) or the infection of mice with *T. muris* (with TNBS treatment) by determining the amounts of IL-4, IL-5 and IFN- γ , does not reasonably provide enablement for a method of screening an helminthic parasite preparation for one or more components that reduce excessive Th1 immune responses, wherein said preparation is prepared by fractionating and sub-fractionating the helminthic preparation is maintained for reasons of record. The specification still does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Applicant argues:

1. Only claim 26 recites the limitations “sub-fraction” or “testing of a sub-fraction in claim 26. Hence, any rejection based on lack of enablement regarding sub-fractions cannot apply to claims 24 and 28-30.
2. The specification teaches sub-fractionation at page 32, lines 7-11.
3. The specification describes fractionation on page 32, lines 4-6.
4. Iterative fractionation and testing of resulting sub-fractions for activity is a well-known and routine method for isolating biologically active component(s) of a complex biological mixture.
5. Palczewski et al. disclose an iterative sub-fractionation approach to purify rhodopsin kinase.
6. Soubeyrand et al. disclose an iterative sub-fractionation approach to purify a Phospholipase A2 enzyme.
7. Ostergaard et al. disclose an iterative sub-fractionation approach to purify L-Glactono- γ -Lactone Dehydrogenase (GLDase).
8. Ma et al. disclose an iterative sub-fractionation approach to purify an Electron-transfer Flavoprotein:Rhodoquione Oxidoreductase (ETF-FO).

9. The specification provides guidance on assays and determination of a Th1 response at a number of places including page 21, line 21 to page 24, line 22 and in Examples.
10. It is not necessary for the specification to describe more than one assay that would function to measure a Th1 immune response in order to be enabling. Thus, the description of assays for IFN- γ , TNF- α and IgG2a are sufficient to meet the enablement requirement with regard to the determination of a Th1 immune response as required by the instant claims.
11. The purified immunomodulatory component(s) identified by the fractionation approach will result in identifying one or more components that reduce an excessive Th1 response.
12. The specification provides guidance with regard to *in vivo* assays at page 30, line 34 to page 34, line 20 and in the Examples.
13. The specification teaches specific animal models for assaying the effect of a HH fraction on an excessive Th1 immune response in Table 1.
14. Example 8 provides details on the use of the mouse EAE model of MS to investigate the effect of schistosomes on autoimmune disease.
15. Attenuation of a Th1-type gut inflammation in mice by treatment of helminthes is shown in Example 3.
16. The specification states in Example 3 that “Injections of HH may prevent any of the autoimmune or excessive inflammatory diseases listed in Table 1”. Hence, one would assay the effect of a fraction or sub-fraction of HH by injecting it into an animal that models disease and monitors symptoms.

Applicant's arguments have been fully considered and deemed non-persuasive.

With regard, to Point 1, the Office agrees with Applicant's assertion that only claim 26 recites the limitations "sub-fraction" or "testing of a sub-fraction in claim 26. However, since the aforementioned rejection is based on the lack of enablement regarding both "fractions" and "sub-fractions" the rejection is deemed valid and hence is maintained.

With regard to Points 2-4, the Office agrees with Applicant's assertion that the methods of obtaining fractions and sub-fractions claimed in the instant claims and iterative methods constitute methods known in the art and hence would have been obvious to one of ordinary skill in the art. However, said methods are not sufficient to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make **and use** the invention commensurate in scope with these claims.

With regard to Points 5-8, the cited references are drawn to methods of purification. Since the instant claims are drawn to methods of screening helminthic parasite preparations for components that reduce an excessive Th1 response, the cited references are not germane and hence are not persuasive.

With regard to Points 9-11, while the specification prophetically discusses the testing of fractions and sub-fractions, it does not disclose how said **fractions and sub-fractions** were used in the assay. Moreover, the specification does not provide guidance as to which biological functions (other than IL-4, IL-5, IgE, IgG1, IgG2a, TNF- α and IFN- γ production) should be tested or **how the testing of said functions would result in identifying "one or more components that reduce an excessive Th1 response"**. The specification gives no guidance as to what degree a given "biological function" has to be enhanced (or inhibited) in order to be deemed to have "reduced an excessive Th1 response. Moreover, the specification does not even

give guidance as to what constitutes an “excessive Th1 response” with regard to given “biological activity”. Finally, the purification of a given component by the fractionation approach would not determine whether said component reduces an excessive Th1 response since the specification provides no correlation between the biological activity of a given component and the effect, if any, it would have on an excessive Th1 response.

With regard to Point 12, the specification is silent on how one would perform the “assay” step of the claimed methods *in vivo*. The specification provides no guidance on what specific “biological activities” are measured, how said “biological activities” are measured or even how samples are obtained. Finally, the specification is silent on **how the testing of said functions would result in identifying “one or more components that reduce an excessive Th1 response”**. Given the total lack of guidance provided by the specification it would require undue experimentation by one of skill in the art to make and use the invention commensurate in scope with the claimed subject matter.

With regard to Point 13, Table 1 merely recites Animal models useful in the study of certain treatable diseases but fails to provide guidance as to how said animal models to be used in the claimed methods.

With regard to Points 14-15, while Example 8 provides details on the use of the mouse EAE model of MS to investigate the effect of schistosomes on autoimmune disease and Example 3 demonstrates the attenuation of a Th1-type gut inflammation in mice by treatment of helminthes, neither demonstrates how the results of the exemplified methods could be correlated with identifying “one or more components that reduce an excessive Th1 response”.

With regard to Point 16, one cannot conclude that the skilled artisan would correlate the statement that "Injections of HH may prevent any of the autoimmune or excessive inflammatory diseases listed in Table 1" with assaying the effect of a fraction or sub-fraction of HH by injecting it into an animal that models disease and monitors symptoms. The aforementioned statement merely contemplates the possible effect of HH injections on autoimmune or excessive inflammatory diseases.

Therefore, for the reasons set forth above the specification is only enabling for an *in vitro* method of determining which helminthic fractions or sub-fractions can affect the immune response in mice co-infected with *M. avium* and *S. mansoni* (either with or without TNBS treatment) or the infection of mice with *T. muris* (with TNBS treatment) by determining the amounts of IL-4, IL-5 and IFN- γ .

35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was

made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

The instant claims are drawn to a method of screening a helminthic preparation for one or more components that reduce an excessive Th1 immune response. The method comprises preparing and fractionating the preparation and assaying the products for the ability to reduce an excessive Th1 immune response.

The rejection of claims 24, 26 and 28-32 under 35 U.S.C. 103(a) as being unpatentable over Pearce et al. (Journal of Exp. Medicine, Vol.173, pages 159-166, 1991) in view of Pearce et al. (PNAS, Vol. 85, pages 5678-5682, 1988) is maintained for reasons of record.

Applicant argues:

1. Pearce et al. (1991) provides no motivation to screen a helminthic parasite preparation for one or more components that reduce an excessive Th1 immune response because it focuses on the beneficial aspects of stimulating Th1 function.
2. The fact that the claims are drawn to screening assays and not to methods of reducing an excessive Th1 response is irrelevant to the alleged obviousness of the claimed invention over the cited references. The context of the references must be still considered in arriving at any motivation to combine the teachings of the references. Since there is no recognition in the cited references that a Th1 immune response is something to avoid, there is no reason one of skill in the art would screen a helminthic parasite preparation for one or more components that reduce an excessive Th1 immune response.

3. There is no teaching in either reference of an “excessive” Th1 immune response.
4. Neither reference discloses the claimed method, nor can they be combined in such a way as to render obvious said method.

Applicant’s arguments have been fully considered and deemed non-persuasive.

With regard to Points 1, 2 and 4, Applicant is reminded that, the instant claims are drawn to a method of screening a helminthic preparation for one or more components that reduce an excessive Th1 immune response. Pearce et al. (1991) disclose a method of measuring various Th1 and Th2 hallmarks. Said method identifies both Th1 enhancers as well as Th1 inhibitors. Hence, the disclosed method comprises preparing and fractionating the preparation and assaying the products for the ability to reduce an excessive Th1 immune response. Moreover, Pearce et al. (1991) discloses that infected mice had a down regulation of Th1 responses (see page 164). Hence, one of skill in the art would have been motivated to identify what stimulus was responsible. The use to which said data would be put is irrelevant since the stated goal of the instant claims was to **identify** one or more components that reduce an excessive Th1 immune response.

Consequently, as outlined in the previous Office action, **Pearce et al. (1991)** disclose a method of identifying antigens from the helminthic parasite *Schistosoma mansoni* for the ability to reduce Th1 responses (see abstract and **pages 164-165**). Said method comprises preparing parasite antigens e.g. cercariae, soluble extracts of schistosomula, adult worms and eggs (see Material and Methods section, page 160) and screening those preparation for the production of either IFN γ (Th1 response cytokine) or IL-5 (Th2 response cytokine)(see figures 1, 5 and Tables 2-3). Pearce et al. (1991), contrary to Applicant’s assertion, clearly disclose, “Th2 response in

infected animals was shown to be induced by schistosome eggs and directed largely against egg antigens" (see abstract lines 10-12). Therefore, **the method disclosed by Pearce et al. (1991)** differs from the claimed invention in that they do not explicitly disclose a method of preparing an helminthic parasite antigen comprising homogenizing, separating homogenate fractions and identifying sub-fractions for biological activity. However, Pearce et al. (1988) disclose a method of preparing antigens from *Schistosoma mansoni* that comprises obtaining adult schistosomes, homogenizing in phosphate buffered saline, centrifuging and purifying by immunoaffinity chromatography (see pages 5678-5679). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to prepare Schistosoma antigens utilizing the homogenization and immunoaffinity column chromatography disclosed by Pearce et al. (1988) and assay the resulting fractions for the ability to reduce excessive Th1 responses utilizing the assay methods disclosed by Pearce et al. (1991). It would have been expected, barring evidence to the contrary, that the purified schistoma antigens would be identified for their ability to reduce excessive Th1 responses because Pearce et al. (1991) specifically identify and compare antigens and their abilities to down regulate Th1 cytokine production. It should be noted that Applicant has maintained that the homogenization and sub fractionation of a helminthic preparation is well known in the art and hence would be obvious to one of ordinary skill in the art.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 32 is rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted steps are: those steps required for “detecting a Th1 response in said mammal”.

Conclusion

No claim is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Zeman whose telephone number is (571) 272-0866. The examiner can normally be reached on Monday- Thursday, 7am -5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (571) 272-0864. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Robert A. Zeman
June 1, 2004

Lynette R. F. Smith
LYNETTE R. F. SMITH
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER